Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Smallpox vaccines: Past, present, and future.

Janie Parrino1, Barney S Graham

  • 1Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892-3017, USA.

The Journal of Allergy and Clinical Immunology
|December 13, 2006
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of <i>Bifidobacterium infantis</i> supplementation on growth, health outcomes, and gut microbiome features in underweight infants from Pakistan.

Frontiers in nutrition·2026
Same author

A structure-based mRNA vaccine for Nipah virus in healthy adults: a phase 1 trial.

Nature medicine·2026
Same author

Potent Monoclonal Antibodies Against Circulating Yellow Fever Virus Strains from Donors Immunized with the 17D Vaccine.

The American journal of tropical medicine and hygiene·2026
Same author

Human Coronavirus HKU1 Neutralizing Monoclonal Antibodies Target Diverse Epitopes Within and Around the TMPRSS2 Receptor Binding Site.

bioRxiv : the preprint server for biology·2025
Same author

Structural convergence and water-mediated substrate mimicry enable broad neuraminidase inhibition by human antibodies.

Nature communications·2025
Same author

Host RhoA Signaling Controls Filamentous vs. Spherical Morphogenesis and Cell-to-Cell Spread of RSV via Lipid Raft Localization: Host-Directed Antiviral Target.

Microorganisms·2025
Same journal

Tamoxifen-driven neutrophil reprogramming protects from pulmonary Granulibacter bethesdensis infection in chronic granulomatous disease.

The Journal of allergy and clinical immunology·2026
Same journal

Clinical and transcriptomic characterization of mixed granulocytic COPD phenotype.

The Journal of allergy and clinical immunology·2026
Same journal

Dupilumab outcomes in pediatric asthma by early eosinophil status: post hoc analysis of VOYAGE/EXCURSION.

The Journal of allergy and clinical immunology·2026
Same journal

Maternal antibiotic exposure alters the newborn metabolomic profile and increases the risk of respiratory infections in offspring: a 13-year longitudinal birth cohort study.

The Journal of allergy and clinical immunology·2026
Same journal

Selective Elimination of Mast Cells via Siglec-6-Targeted Nanodelivery of Drug Payload.

The Journal of allergy and clinical immunology·2026
Same journal

Loss of epidermal miR-149 sensitizes to skin inflammation.

The Journal of allergy and clinical immunology·2026
See all related articles

Smallpox eradication was a success, but remaining variola virus poses a bioterror threat. New, safer poxvirus vaccines are in development for potential use against smallpox and other diseases.

Area of Science:

  • Virology and Immunology
  • Vaccine Development
  • Public Health Preparedness

Background:

  • Global smallpox eradication achieved through vaccination, but live variola virus stocks remain.
  • Concerns exist regarding potential bioterrorism use of variola virus, necessitating preparedness.
  • Historical smallpox vaccine has significant safety concerns and outdated manufacturing processes.

Purpose of the Study:

  • To address the ongoing threat posed by residual variola virus stocks.
  • To explore the development of novel, safer poxvirus vaccines.
  • To investigate the potential of new vaccines against orthopoxviruses and for therapeutic applications.

Main Methods:

  • Review of historical smallpox vaccine efficacy and adverse events.
  • Exploration of alternative vaccine technologies: replication-defective viruses, gene-based vectors, subunit vaccines.

Related Experiment Videos

  • Consideration of challenges in efficacy evaluation for new vaccines without natural variola virus exposure.

    • Main Results:

    • Development of alternative poxvirus vaccines focuses on improving safety and immunogenicity.
    • New vaccine candidates aim for broader utility against orthopoxviruses like monkeypox.
    • Recombinant poxvirus vectors show promise for treating and preventing various diseases.

    Conclusions:

    • Despite eradication, the threat of variola virus necessitates continued vigilance and vaccine development.
    • Novel poxvirus vaccines offer improved safety profiles compared to the historical vaccine.
    • Emerging poxvirus vaccine technologies hold potential beyond smallpox, including against monkeypox and for broader disease prevention.